Neuromyelitis optica News and Research

RSS
Viropharma announces financial results for second quarter of 2013

Viropharma announces financial results for second quarter of 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Study applying OPKO Health's technology to identify synthetic peptoid in NMO patient serum published

Study applying OPKO Health's technology to identify synthetic peptoid in NMO patient serum published

Autoantibody aids identification of hyperexcitability disorders

Autoantibody aids identification of hyperexcitability disorders

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo researchers discover new therapy for patients with neuromyelitis optica

Plasma exchange is beneficial additive to optic neuritis treatment

Plasma exchange is beneficial additive to optic neuritis treatment

Alexion second quarter net product sales increase to $274.7 million

Alexion second quarter net product sales increase to $274.7 million

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Aquaporin-4 plays a key role in brain inflammation

Aquaporin-4 plays a key role in brain inflammation

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

NMO patients are misdiagnosed with Multiple Sclerosis, says Mayo Clinic neurologist

Aquaporin-4 is the first specific molecule to be defined as a target for the autoimmune response in any form of MS

Aquaporin-4 is the first specific molecule to be defined as a target for the autoimmune response in any form of MS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.